IP Library Granted Patent US 7,807,716
Granted Patent B2
US 7,807,716 · App. 12/565,347 · Granted Oct 5, 2010

Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use

Assignee: Oral Delivery Technology Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,716
App. No.
12/565,347
Granted
Oct 5, 2010
Kind
B2
Abstract

There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. Also provided are compositions for increasing nitric oxide physiological levels in a subject, methods for increasing nitric oxide physiological levels in a subject, methods for improving a subject's muscle strength, athletic performances and/or lean body mass gain and or performance in a subject.

Claims (13)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof.

2. A composition for increasing nitric oxide physiological levels in a subject, which comprises a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

3. The composition according to claim 2 , wherein said pharmaceutically acceptable carrier is chosen from, propylene glycol monocaprylate, propylene glycol, water, sodium lauryl sulfate, salt solutions, alcohol, vegetable oils, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose and polyvinylpyrrolidon.

4. The composition according to claim 2 , wherein said pharmaceutically acceptable carrier is saliva-absorbing microcrystalline cellulose.

5. The composition according to claim 2 , which is formulated as a liquid formulation, a liquid dosage form, an enteric-coated soft-gel capsule, a capsule, a sustained-release capsule, a tablet, a sustained release tablet, a chewable tablet, a sublingual tablet, an effervescent tablet, a pill, powders, granules, gels and suppositories.

6. The composition according to claim 2 , which further comprises creatine.

7. The composition according to claim 2 , further comprising a vasodilatory compound chosen from L-arginine, norvaline, and citrulline.

8. A method for increasing nitric oxide physiological levels in a subject, which comprises administering a sufficient amount of the composition of claim 2 .

9. The method according to claim 8 , wherein said administration is oral, bucal, parenteral, transdermal, rectal, by inhalation, by topical application or by injection.

10. The method according to claim 8 , wherein said administration is oral.

11. The method according to claim 8 , wherein said amount is a daily total dosage of about 0.05 to 1000 mg.

12. The method according to claim 11 , wherein said daily total dosage is administered at least once a day.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2015
From: BENOIT & CÔTÉ, INC.
To: NITROGENIX,INC; ORAL DELIVERY TECHNOLOGY, LTD
Reel/Frame 036121/0920 →
SECURITY AGREEMENT Recorded Jul 26, 2013
From: NITROGENIX INC.; ORAL DELIVERY TECHNOLOGY LTD.
To: BENOIT & COTE
Reel/Frame 030900/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2009
From: FARBER, MICHAEL
To: ORAL DELIVERY TECHNOLOGY LTD.
Reel/Frame 023274/0606 →
Continuity (2)
Provisional Application 6109962100 · Sep 24, 2008
Related Publication 20100076043A1 · Mar 25, 2010